MeSH tree: D02.886.778
Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence. But a new study suggests that the choice of blood thinner may influence how ...
Apr 27, 2026
0
5
New findings show that switching to clopidogrel, a blood thinner, alone after one year of dual antiplatelet therapy (DAPT) leads to better outcomes than aspirin, even in patients at high risk of bleeding and those who had ...
Apr 24, 2026
0
5
A randomized trial conducted by the Alliance for Clinical Trials in Oncology has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by ...
Apr 11, 2026
0
6
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, ...
Mar 11, 2026
0
23
Patients with atrial fibrillation who are prescribed diltiazem to control heart rate alongside anticoagulants (blood thinners) such as apixaban or rivaroxaban face a higher risk of serious bleeding compared with those taking ...
Feb 27, 2026
0
8
Fibromyalgia is a long-term chronic condition that causes widespread pain in the muscles and soft tissues throughout the body. The illness can affect people of all ages and has a major impact on quality of life, often making ...
A research team has demonstrated that clopidogrel is more effective than aspirin as a long-term antiplatelet therapy in patients at high risk of recurrent cardiovascular events after coronary stent implantation. The team ...
Feb 5, 2026
0
12
The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new research led by Oregon ...
Dec 15, 2025
0
21
The UK Center of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK CERSI-PGx), led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication ...
Dec 4, 2025
0
14
One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit ...
Nov 10, 2025
0
15
